What is the usual recommended dose of ondansetron (Zofran) orally disintegrating tablets (ODT) for adults and children?

Ondansetron ODT Dosing Recommendations

Adult Dosing

For adults, the standard ondansetron ODT dose is 8 mg, with frequency and duration determined by clinical indication: 8 mg twice daily for moderate-risk chemotherapy, 16–24 mg once daily for high-risk chemotherapy, and 8 mg as needed for postoperative nausea. 1, 2

Chemotherapy-Induced Nausea and Vomiting

• Moderate emetogenic risk: 8 mg ODT administered 30 minutes before chemotherapy, then 8 mg twice daily for 1–2 days post-treatment, always combined with dexamethasone 8–12 mg for optimal efficacy 1, 2
• High emetogenic risk: 16–24 mg ODT once daily on day 1, followed by 8 mg twice daily on days 2–3, mandatory triple therapy with dexamethasone 12 mg and an NK1-receptor antagonist (ondansetron monotherapy is insufficient) 1, 2
• Low emetogenic risk: 8 mg ODT twice daily on the day of chemotherapy only, no subsequent dosing required 1, 2

Radiation-Induced Nausea and Vomiting

• High-risk radiation (total body irradiation or upper abdomen): 8 mg ODT before each radiation fraction, continued daily on radiation days plus 1–2 days after completion, combined with dexamethasone 4 mg 1, 2
• Moderate-risk radiation: 8 mg ODT once daily before radiation, used prophylactically on radiation days only 1

Postoperative Nausea and Vomiting

• Single dose: 16 mg ODT administered 1 hour before induction of anesthesia 3

Critical Safety Limits

• Maximum single dose: 16 mg (higher doses increase QT prolongation risk) 1, 2
• Maximum daily dose: 32 mg via any route 1, 2
• Cardiac monitoring: Required in patients with electrolyte abnormalities, congestive heart failure, or concomitant QT-prolonging medications 1

---

Pediatric Dosing

For children, ondansetron ODT is dosed at 0.15 mg/kg per dose (maximum 16 mg per dose), with specific age restrictions and clinical context determining appropriateness. 1, 4

Weight-Based Dosing for Chemotherapy

• Standard dose: 0.15 mg/kg (or 5 mg/m²) IV or oral, administered 30 minutes before chemotherapy, repeated every 8 hours as needed 1, 4
• Maximum single dose: 16 mg regardless of weight 1, 5
• Combination therapy: Add dexamethasone for moderate-to-high emetogenic chemotherapy to improve efficacy 1, 4

Practical Dosing Examples by Weight

• Child weighing 20 kg: 0.15 mg/kg = 3 mg per dose (round to nearest available 4 mg ODT) 1
• Child weighing 40 kg: 0.15 mg/kg = 6 mg per dose (round to 8 mg ODT) 1
• Child weighing ≥53 kg: 0.15 mg/kg = 8 mg per dose (standard adult dose) 1

Acute Gastroenteritis (Age-Restricted Indication)

• Age requirement: Only for children ≥4 years old (insufficient safety data below this age) 1
• Dose: Single 0.15 mg/kg dose (rounded to nearest 4 mg or 8 mg ODT), maximum 8 mg 1
• Frequency: Single dose only; repeat dosing for uncomplicated gastroenteritis is not recommended 1
• Contraindication: Avoid when toxic megacolon is suspected or in inflammatory diarrhea with fever 1

Pediatric Safety Considerations

• Cardiac risk: Single IV doses >4 mg in pediatric patients increase QT prolongation risk; ECG monitoring advised with risk factors 1
• Common adverse effect: Increased stool volume/diarrhea reported in pediatric gastroenteritis studies 1
• Infants <6 months: Ondansetron should not be used for food protein-induced enterocolitis syndrome due to limited safety data 1

---

Available ODT Formulations

• Tablet strengths: 4 mg and 8 mg orally disintegrating tablets 1, 2
• Oral soluble film: 8 mg (bioequivalent to ODT formulation) 1, 6
• Administration: Dissolves rapidly on tongue without water; water is optional 6, 7

---

Key Prescribing Pitfalls to Avoid

• Never use ondansetron monotherapy for moderate-to-high emetogenic chemotherapy; combination with dexamethasone (and NK1 antagonist for high-risk) is mandatory 1, 2
• Do not exceed 16 mg single IV dose due to dose-dependent QT prolongation documented in FDA safety reviews 1, 2
• Avoid indefinite daily dosing: Ondansetron should be limited to specific treatment windows (chemotherapy days, radiation days) rather than continuous administration 8
• For breakthrough nausea: Add agents from different drug classes (metoclopramide, prochlorperazine) rather than simply increasing ondansetron frequency 1, 2
• Timing matters: Administer at least 30 minutes before chemotherapy or 1 hour before anesthesia for optimal 5-HT₃ receptor blockade 1, 2